Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, announces that it has completed its previously announced acquisition of PathAI Diagnostics from PathAI, with the goal to accelerate the adoption of AI and digital pathology to improve the diagnosis of cancer and other diseases. PathAI remains an independent company, dedicated to advancing AI and digital pathology solutions for biopharmaceutical companies and pathology laboratories. The transaction will support PathAI’s strategy to scale its investments in AI technology and expand its software and algorithm business. In connection with the acquisition, the PathAI Diagnostics state-of-the-art digitized laboratory in Memphis has been rebranded as AmeriPath.
Read the full article: Quest Diagnostics Completes Acquisition of Select PathAI Diagnostics’ Lab Assets from PathAI //
Source: https://www.prnewswire.com/news-releases/quest-diagnostics-completes-acquisition-of-select-pathai-diagnostics-lab-assets-from-pathai-accelerating-adoption-of-ai-and-digital-pathology-to-speed-cancer-diagnosis-302168364.html